Literature DB >> 16020143

Improvements in SSRI/SNRI-induced sexual dysfunction by switching to escitalopram.

Adam Keller Ashton1, Ahsan Mahmood, Farhan Iqbal.   

Abstract

Antidepressants, especially serotonin reuptake inhibiting agents, are associated with sexual dysfunction. The newest drug of this class, escitalopram, claims greater tolerability than older alternatives. This study evaluated patient experiences with switching from one serotonin enhancing antidepressant to escitalopram in individuals who already were complaining of antidepressant-induced sexual dysfunction. We found that 68.1% of patients experienced improvement with their sexual function. The ability to obtain a satisfactory clinical response at relatively low doses may explain this finding. We performed gender, phase of sexual response,and dose analyses. This article discusses results and significance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16020143     DOI: 10.1080/00926230590513474

Source DB:  PubMed          Journal:  J Sex Marital Ther        ISSN: 0092-623X


  8 in total

1.  Comprehensive self-management reduces the negative impact of irritable bowel syndrome symptoms on sexual functioning.

Authors:  Margaret D Eugenio; Sang-Eun Jun; Kevin C Cain; Monica E Jarrett; Margaret M Heitkemper
Journal:  Dig Dis Sci       Date:  2012-06       Impact factor: 3.199

Review 2.  Escitalopram: a review of its use in the management of major depressive disorder.

Authors:  David Murdoch; Susan J Keam
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Escitalopram: a review of its use in the management of major depressive disorder in adults.

Authors:  Karly P Garnock-Jones; Paul L McCormack
Journal:  CNS Drugs       Date:  2010-09       Impact factor: 5.749

4.  Patients' attitudes toward side effects of antidepressants: an Internet survey.

Authors:  Toshiaki Kikuchi; Hiroyuki Uchida; Takefumi Suzuki; Koichiro Watanabe; Haruo Kashima
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-07-15       Impact factor: 5.270

5.  Acute caffeine reverses the disruptive effects of chronic fluoxetine on the sexual behavior of female and male rats.

Authors:  Brunella V González Cautela; Gonzalo R Quintana; Jessica Akerman; James G Pfaus
Journal:  Psychopharmacology (Berl)       Date:  2020-11-26       Impact factor: 4.530

6.  Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability.

Authors:  Eiji Kirino
Journal:  Patient Prefer Adherence       Date:  2012-12-04       Impact factor: 2.711

7.  Sexual function in nondepressed women using escitalopram for vasomotor symptoms: a randomized controlled trial.

Authors:  Susan D Reed; Katherine A Guthrie; Hadine Joffe; Jan L Shifren; Rebecca A Seguin; Ellen W Freeman
Journal:  Obstet Gynecol       Date:  2012-03       Impact factor: 7.623

8.  Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR.

Authors:  Jana Strohmaier; Stefan Wüst; Rudolf Uher; Neven Henigsberg; Ole Mors; Joanna Hauser; Daniel Souery; Astrid Zobel; Mojca Z Dernovsek; Fabian Streit; Christine Schmäl; Dejan Kozel; Anna Placentino; Anne Farmer; Peter McGuffin; Katherine J Aitchison; Marcella Rietschel
Journal:  World J Biol Psychiatry       Date:  2011-03-09       Impact factor: 4.132

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.